60 DEGREES PHARMA INC

SXTPNASDAQ

🏆 #5205 by market capUS Equity

$695.14▼ $28.15 (−4.05%)

Simulated price

🔔

Track SXTP

Get earnings, price moves & breaking news on Telegram

Track

24h▼ 4.0%

7d—

14d—

30d—

ytd—

1y—

🏦Market Cap

$4M

Small Cap

📈Revenue Growth (YoY)

+24.8%

Healthy

📊Gross Margin

26.3%

Moderate

💵FCF Margin

—

⚖️P/S Ratio

3.4x

Fair

Otter Score

Weak

No chart data available for SXTP.

Trading Snapshot

Day Range: $691.90 – $707.73
52-Week Range: $0.84 – $8.62
Volume: $3.07B
Avg Volume: $3.46B
Shares Outstanding: 2.7M
Next Earnings: Dec 10, 2026

Fundamentals Snapshot

Annual Revenue: $1M
Last Q Revenue: $207,898
P/E Ratio: —
P/S Ratio: 3.4x
EPS (TTM): $-5.93
Dividend Yield: —
Dilution (1yr): +720.6%

Why Investors Own SXTP

✓High-growth profile — revenue up -8.5% YoY with expanding US Equity exposure.
✓Healthy economics — 51% gross margin and 30% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

60 DEGREES PHARMA INC

SXTP

Financial Trends

Revenue

$1M▲ +65.5% YoY

Gross Margin

22.3%▼ −39.3% YoY

Operating Income

−$8M▼ −20.1% YoY

Free Cash Flow

−$7M▲ +21.2% YoY

Shares Outstanding

1.2M▲ +720.6% YoY

Net Cash

$1M▼ −$146K YoY

StockOtter · stockotter.space

About 60 DEGREES PHARMA INC

60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.

🦦